3/5/2024

Methylprednisolone Sodium Succinate Injection

Products Affected - Description

- Methylprednisolone Sodium Succinate powder for solution for injection, Fresenius Kabi, 125 mg, single dose vial, 25 count, NDC 63323-0258-03
- Methylprednisolone Sodium Succinate powder for solution for injection, Fresenius Kabi, 40 mg, single dose vial, 25 count, NDC 63323-0255-03

Reason for the Shortage

- Pfizer has Solu-Medrol available.
- Fresenius Kabi did not provide a reason for the shortage.
- Hikma has methylprednisolone sodium succinate injection available.

Available Products

- Solu-Medrol injection, Pfizer, 1 gram, single dose vial, 1 count, NDC 00009-0698-01
- Solu-Medrol injection, Pfizer, 1 gram, Act-O-Vial single dose vial, 1 count, NDC 00009-0018-20
- Solu-Medrol injection, Pfizer, 125 mg, Act-O-Vial single dose vial, 25 count, NDC 00009-0047-22
- Solu-Medrol injection, Pfizer, 2 gram, single dose vial, 1 count, NDC 00009-0850-01
- Solu-Medrol injection, Pfizer, 40 mg, Act-O-Vial single dose vial, 25 count, NDC 00009-0039-28
- Solu-Medrol injection, Pfizer, 500 mg, Act-O-Vial single dose vial, 1 count, NDC 00009-0003-02
- Solu-Medrol injection, Pfizer, 500 mg, single dose vial, 1 count, NDC 00009-0758-01
- Methylprednisolone Sodium Succinate powder for solution for injection, Fresenius Kabi, 1 gram, single dose vial, 1 count, NDC 63323-0265-30
- Methylprednisolone Sodium Succinate powder for solution for injection, Hikma, 1 gram, single dose vial, 1 count, NDC 00143-9851-01
- Methylprednisolone Sodium Succinate powder for solution for injection, Hikma, 125 mg, single dose vial, 25 count, NDC 00143-9754-25
- Methylprednisolone Sodium Succinate powder for solution for injection, Hikma, 40 mg, single dose vial, 25 count, NDC 00143-9753-25
- Methylprednisolone Sodium Succinate powder for solution for injection, Hikma, 500 mg, single dose vial, 1 count, NDC 00143-9850-01

Estimated Resupply Dates

- Fresenius Kabi has methylprednisolone sodium succinate 40 mg and 125 mg vials on back order and the company estimates a release date of early- to mid-April 2024 for the 40 mg vials and early-March 2024 for the 125 mg vials.

Updated

Updated March 5, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 23, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.